TCT-429
Short- and intermediate-term clinical outcomes after implantation of everolimus-eluting bioresorbable scaffold in complex lesions: a prospective single-arm study - ABSORB Expand trial

Robert J. Van Geuns1, Peter De Jaegere1, Roberto Dildeti2, Antonios Karanassos3, Takaaki Muramatsu4, Sjoerd T. Nauta5, Ysishooh Onuma6, Evelyn Regar1, Carl J. Schultz7, Patrick W. Serruys8, Nicolas M. Van Mieghem1, Felix Zijlstra1
1Erasmus MC, Rotterdam, Netherlands, 2Thoraxcenter, Erasmus Medical Center, Rotterdam, Rotterdam, Netherlands, 3Thoraxcenter, Rotterdam, The Netherlands, 4Thoraxcenter, Erasmus MC, Rotterdam, Zuid Holland, 5Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands, 6ThoraxCenter, Rotterdam, Rotterdam, Netherlands, 7Thoraxcenter, Rotterdam, Rotterdam, Netherlands, 8Erasmus University Medical Center, Rotterdam, Netherlands

Background: Bioresorbable scaffold is a novel approach that provides transient risk lesions and high-risk patients, the ABSORB BVS had good short term results. In a patient population including one target lesion, due to recurrent angina pectoris, at least 1 month follow-up was available in 94 patients (median follow up 54 days; Q1-Q3 40-67). MACE occurred in 4 patients (4.2%). Two patients experienced MI due to subacute scaffold thrombosis and two patients needed target vessel revascularization, including one target lesion, due to recurrent angina pectoris. In a patient population reflecting daily clinical practice, including high-risk lesions and high-risk patients, the ABSORB BVS had good short term results.

TCT-431
Angiographic Results of a novel Novolimus Eluting Bioresorbable Coronary Scaffold System (NEBCSS) for the treatment of single de-novo coronary artery lesions in 6 month Serial QCA analysis results from the pivotal, prospective, multicentre, DESolve Nx Trial

Ricardo A. Costa1, Stefan Verbeyse2, Joachim Schofer3, José de Costa Jr4, Daniel Chiumie5, Andrea Abizaid6, Yan John7, Vinayak Bhija8, Lynn Morrison9, Sara Toslov1, Alexandre Abizaid2
1Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, 2Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, 3Antwerp, Belgium, 4Medicare center Prof Mathey, Prof Schofer, Hamburg University Cardiovascular Center, Hamburg, Germany, 5Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, 6Instituto Dante Pazzanese, Sao Paulo, Brazil, 7N/A, Sao Paulo, Brazil, 8Elixir Medical Corporation, Sunnyvale, CA, 9Elixir medical corporation, Sunnyvale, CA, 10Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

Background: By design, drug-eluting bioresorbable scaffolds have been developed as an alternative to metallic stents in order to provide temporary vascular scaffolding, prevent vessel recoil and inhibit late clinical events due to excessive neointimal hyperplasia formation including restenosis and lesion revascularization. The DESolve® bioresorbable scaffold (Elixir Medical Co., Sunnyvale, CA) is a novel device combining a PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and a potent anti-proliferative sirolimus metabolite Novolimus, with a drug dose of 5 mcg per mm of scaffold length. Our objective was to report serial QCA results from the prospective, non-randomized, single-arm multicentre DESolve Nx trial.

Methods: A total of 126 patients/lesions were enrolled in 13 sites in Europe, New Zealand and Brazil. Lesion criteria were single de novo lesion <14 mm in length, located in native coronary vessels 2.75-3.50 mm in diameter, with stenosis between 50-90% and TIMI flow >2. The study device was available in 3.00, 3.25 and 3.50 mm in diameter and 14 and 18 mm in length. All patients were assigned to angiographic follow-up at 6 months. Quantitative coronary angiography (QCA) analysis was performed at an independent angiographic core laboratory.

Results: Overall, mean age was 62 years and 21% had diabetes. Target lesions were evenly distributed in LAD, LCx and RCA, and most lesions were classified as type B (71%) according to the ACC/AHA classification. During procedure, the study device was successfully implanted in 122/126 cases (97%). Serial QCA results are shown in the Table.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Preprocedure</th>
<th>Postprocedure</th>
<th>6-Month Follow-up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>126</td>
<td>126</td>
<td>113</td>
</tr>
<tr>
<td>Lesion length, mm</td>
<td>11.20 ± 3.77</td>
<td>11.20 ± 3.77</td>
<td>11.20 ± 3.77</td>
</tr>
<tr>
<td>Reference diameter, mm</td>
<td>3.06 ± 0.31</td>
<td>3.09 ± 0.26</td>
<td>3.01 ± 0.29</td>
</tr>
<tr>
<td>MLD, mm</td>
<td>0.92 ± 0.40</td>
<td>2.67 ± 0.28</td>
<td>2.45 ± 0.44</td>
</tr>
<tr>
<td>% DS</td>
<td>69.9 ± 12.3</td>
<td>13.5 ± 7.8</td>
<td>18.3 ± 13.6</td>
</tr>
<tr>
<td>Acute gain, mm</td>
<td>1.73 ± 0.45</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>% acute recoil, mm</td>
<td>6.6 ± 6.2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Late lumen loss, mm</td>
<td>-</td>
<td>0.21 ± 0.34</td>
<td>-</td>
</tr>
</tbody>
</table>

Conclusions: Angiographic results of the novel DESolve bioresorbable scaffold showed promising results in de novo coronary artery lesions including relatively low in-scaffold late lumen loss, a surrogate of neointimal hyperplasia, at 6-month follow-up.

TCT-430
ABSORB everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in daily clinical practice. A single center registry analysis

Mariëlla E. Hassell1, Robin P. Kraak2, Maik J. Grundeken3, Karel T. Koch3, Jose P. Henriques3, Jan Baan Jr2, Marije M. Vis3, Karin Arkenbout2, Jan G. Tijssen3, Daniel Chamié5, Andrea Abizaid6, Yan John7, Vinayak Bhija8, Lynn Morrison9, Charbel Naim1, Antonio Colombo3
1San Raffaele Scientific Institute, Milan, Italy, 2San Raffaele Scientific Institute, Milan, Italy, 3San Raffaele Scientific Institute, Milano, Milano, 4EMO GVM Centro Cuore ColumbusSan Raffaele Hospital, Milan, Italy

Background: The ABSORBTM bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA, USA) is a resorbable polymeric scaffold that provides vessel support with drug delivery capability without the long-term limitations of metallic drug-eluting stents. The everolimus-eluting bioresorbable scaffold (ABSORB; Abbott vascular, CA, USA) has been shown to be effective in the context of first-in-man trials including simple lesion(s). However, the effect of ABSORB implantation in more complex patients cannot be directly extrapolated from these findings. We sought to assess patient impact of ABSORB with "real world" data short- and intermediate-term clinical outcomes in a real-life population with complex lesions.

Methods: Since September 1st, 2013, our institution commenced the use of ABSORB scaffold in patients with complex lesions including a long lesion (8 cm or longer in length), a calcified lesion, a bifurcation lesion and a large vessel with a diameter of ≥4 mm. Patients presenting with stable angina, unstable angina and non-ST elevation myocardial infarction were included. In total 300 patients presenting with de novo complex lesions will be treated exclusively with ABSORB scaffold.

Results: Up to May 1, 2013, 137 patients were included in the study. In total 248 scaffolds were implanted, with a procedural success rate of 95%, in the lesions including 40 bifurcations and 11 chronic total occlusions. In 52 patients (53 lesions), more than one scaffold was implanted with overlap. An interim analysis of the population at one month revealed no MACE event except for one myocardial infarction. The enrolment is ongoing while the updated one-month and 6-month data on the occurrence of death, MI, repeat revascularization and scaffold thrombosis are currently being collected and will be presented at time of the meeting. Survival information will be obtained from municipal civil registries.

Conclusions: The short-term and intermediate-term clinical safety and efficacy of the ABSORB scaffold in complex lesions will be presented at the meeting.

TCT-432
Angiographic Results of the Novel DESolve Bioresorbable Scaffold in Complex Lesions

Tora Nagamuma1, Azem Laith2, Charis Costopulos3, Filippo Figini4, Charbel Naim1, Antonio Colombo5
1San Raffaele Scientific Institute, Milan, Italy, 2San Raffaele Scientific Institute, Milano, Milano, 3EMO GVM Centro Cuore ColumbusSan Raffaele Hospital, Milan, Italy

Background: The use of bioresorbable vascular scaffolds (BVS) has largely been restricted to simple lesions with a relatively small number of patients treated with complex lesions. The aim of this study was to evaluate the device success and short-term clinical outcomes of BVS in realistic world patients including those with complex coronary lesions.

Methods: All consecutive patients treated with BVS between May 2012 and June 2013 were included in this analysis. At 2 centres were included in this analysis.

Results: A total of 123 lesions in 82 patients (87.8% male, mean age 66.4 years) were treated with BVS. Complex lesions were distributed as follows: long lesion >20mm (n=83), bifurcation lesions (n=49), calcified lesions (n=42), chronic total occlusions (n=9) and in-stent restenoses (n=7). One feature can be present in more than one lesion. Intracoronary vascular ultrasound and optical computed tomography were used in 85.4% and 20.3% of cases, respectively. Pre-dilation was performed in 98.4%, while post-dilation (mean 21.5 atm) was utilized in all cases. Tobutation or scoring balloon was used in 22.0%. Device success was achieved in 99.2%. At median follow-up of 147